Prediction of Fetal Maturity and Neonatal Morbidity Using Novel Biomarkers from Cell-Free Amniotic Fluid Transcriptome

点击翻译按钮获取中文摘要

PROJECT SUMMARY Multiple research agencies addressing the complex public health problem of preterm birth have emphasized conducting research to identify biomarkers that could improve clinical risk assessment for preterm birth. Late- preterm infants (34 to <37 weeks gestation) comprise 74% of premature births, and are most responsible for the increased rates of premature deliveries in the U.S. During this time, obstetricians struggle to make delivery- planning decisions where uncertainty exists regarding benefit vs. risk for mother and baby, and the only currently available fetal maturity testing focuses on the lung. For this high-risk late-preterm population, identification of fetal biomarkers that predict physiologic readiness for postnatal life is critical for obstetrical and neonatal risk assessment, particularly when maturational processes have different trajectories for individual infants. Amniotic fluid (AF) both contributes to and reflects fetal well-being, and contains an abundant proportion of cell- free fetal DNA and RNA that can be targeted quantitatively for ease of application, specificity, and broader representation of cell types than protein or metabolites. Our preliminary work has demonstrated that this cell- free fetal RNA/DNA can be isolated and analyzed to produce a snapshot of overall fetal maturity, thereby making analysis of amniotic fluid a practical first step to discovery of novel biomarkers that can then be identified in maternal serum. This R21 will continue our discovery driven preliminary work by further elucidating the following hypothesis: The AF RNA transcriptome will exhibit RNA expression patterns that identify the state of fetal organ maturity, and will predict neonatal morbidity. Aim 1 will describe differences in the amniotic fluid transcriptome at 4 different time points in pregnancy to describe the trajectory of physiologic processes occurring with advancing gestation. Aim 2(a) will identify candidate biomarkers for lung and other organ maturity by determining differences in amniotic fluid RNA expression between preterm infants (32 to <38 weeks) with and without common adverse neonatal outcomes. Aim 2(b) will then test the predictive capacity of the candidate biomarkers identified using a separate validation cohort, and compare the specificity and sensitivity for predicting fetal maturity, compared to current methods of fetal lung maturity testing. The proposed research has the potential impact to illustrate the transcriptomic profiles that are dynamically changing across fetal development and to inform the timing of non-indicated deliveries, significantly reducing maternal complications and neonatal morbidity resulting from prematurity, or to allow for other interventions to be administered to ameliorate fetal maturity (antenatal corticosteroids). By better informing the timing of late- preterm deliveries, we can reduce maternal and neonatal complications resulting from prematurity, a major public health concern.